Liwen Zhao

Guangdong 518036, PR China
Puerto Rico

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Retraction notice to "MiR-23a-3p acts as an oncogene and potential prognostic biomarker by targeting PNRC2 in RCC" Biomed. Pharmacother. 110(2019) 656-666.

Retraction notice to "MiR-23a-3p acts as an oncogene and potential prognostic biomarker by targeting PNRC2 in RCC" Biomed. Pharmacother. 110(2019) 656-666.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: July 06, 2024

Corrigendum to "MiR-302b regulates cell functions and acts as a potential biomarker to predict recurrence in bladder cancer" [Life Sciences, 209 (2018) 15-23].

Corrigendum to "MiR-302b regulates cell functions and acts as a potential biomarker to predict recurrence in bladder cancer" [Life Sciences, 209 (2018) 15-23].

Journal: Life sciences

Published: October 27, 2023

A novel bispecific antibody as an immunotherapeutic agent in hepatocellular carcinoma.

A novel bispecific antibody as an immunotherapeutic agent in hepatocellular carcinoma.

Journal: Molecular immunology

Published: March 27, 2023

Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.

Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.

Journal: International immunopharmacology

Published: March 22, 2020

Corrigendum to "MiR-23a-3p acts as an oncogene and potential prognostic biomarker by targeting PNRC2 in RCC" [Biomed. Pharmacother. 110 (2019) 656-666].

Corrigendum to "MiR-23a-3p acts as an oncogene and potential prognostic biomarker by targeting PNRC2 in RCC" [Biomed. Pharmacother. 110 (2019) 656-666].

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: March 16, 2019

Associations of high expression of miR-106b-5p detected from FFPE sample with poor prognosis of RCC patients.

Associations of high expression of miR-106b-5p detected from FFPE sample with poor prognosis of RCC patients.

Journal: Pathology, research and practice

Published: October 12, 2018

Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent.

Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent.

Journal: International journal of pharmaceutics

Published: September 19, 2018

MiR-302b regulates cell functions and acts as a potential biomarker to predict recurrence in bladder cancer.

MiR-302b regulates cell functions and acts as a potential biomarker to predict recurrence in bladder cancer.

Journal: Life sciences

Published: May 25, 2018

Oncogene miR-154-5p regulates cellular function and acts as a molecular marker with poor prognosis in renal cell carcinoma.

Oncogene miR-154-5p regulates cellular function and acts as a molecular marker with poor prognosis in renal cell carcinoma.

Journal: Life sciences

Published: April 17, 2018

Oncogene miR-187-5p is associated with cellular proliferation, migration, invasion, apoptosis and an increased risk of recurrence in bladder cancer.

Oncogene miR-187-5p is associated with cellular proliferation, migration, invasion, apoptosis and an increased risk of recurrence in bladder cancer.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: April 11, 2018

miR-566 functions as an oncogene and a potential biomarker for prognosis in renal cell carcinoma.

miR-566 functions as an oncogene and a potential biomarker for prognosis in renal cell carcinoma.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: February 12, 2018

Showing 1-11 of 11

Last Updated: 09/26/2026